Safety and Immune Response to FMPV-1

Summary

This is a single centre, open-label, non-randomized, Phase I study assessing safety and immune response of FMPV-1 in healthy male subjects.

Timeline

Start

2022-01-31

Primary completion

2022-10-31

Completion

2023-06-30

Publications

• Inderberg EM, Singh N, Miller R, Arbe-Barnes S, Eriksen HK, Lversen B, Juul HV, Eriksen JA, Handeland KR. Generation of frameshift-mutated TGFbetaR2-specific T cells in healthy subjects following administration with cancer vaccine candidate FMPV-1/GM-CSF in a phase 1 study. Cancer Immunol Immunother. 2025 Feb 25;74(4):115. doi: 10.1007/s00262-025-03969-6.

Drugs

Indications